{
    "Trade/Device Name(s)": [
        "HemosIL CL HIT-IgG(PF4-H)"
    ],
    "Submitter Information": "Instrumentation Laboratory (IL) Company",
    "510(k) Number": "K243374",
    "Predicate Device Reference 510(k) Number(s)": [
        "K170854"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCO"
    ],
    "Summary Letter Date": "January 28, 2025",
    "Summary Letter Received Date": "October 30, 2024",
    "Submission Date": "October 30, 2024",
    "Regulation Number(s)": [
        "21 CFR 864.7695"
    ],
    "Regulation Name(s)": [
        "Platelet Factor 4 Radioimmunoassay"
    ],
    "Analyte Class(es)": [
        "hematology",
        "immunology"
    ],
    "Analyte(s)": [
        "Anti-PF4/Heparin IgG Antibodies"
    ],
    "Specimen Type(s)": [
        "Human 3.2% citrated plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ACL TOP 970 CL"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CIA)"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control",
        "Cartridge"
    ],
    "Document Summary": "FDA 510(k) summary for HemosIL CL HIT-IgG(PF4-H) chemiluminescent immunoassay for detecting anti-PF4/heparin IgG antibodies in citrated plasma on ACL TOP 970 CL analyzer.",
    "Indications for Use Summary": "Qualitative, fully automated chemiluminescent immunoassay for detection of IgG antibodies against Platelet Factor 4 complexed to heparin, aiding risk determination for heparin induced thrombocytopenia (HIT) in adult patients suspected of HIT, for use with human 3.2% citrated plasma on the ACL TOP 970 CL in a laboratory setting; result aids but does not exclude HIT and is for prescription use only.",
    "fda_folder": "Hematology"
}